Merck Serono

/K I L L K I L L K I L L -- Merck Serono/

We are advised by Merck Serono that journalists and other readers should disregard the news release "Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer" NYSE:SRA, issued today due to premature release. This release will be reissued at a later date. ots Originaltext: Merck Serono Im Internet recherchierbar: http://www.presseportal.ch Contact: Contact: Dr. Raphaela Farrenkopf, Phone +49-6151-72-2274

Das könnte Sie auch interessieren: